Preclinical efforts have identified efficacious CARs targeting GPC2 that are in clinical development across different centers in the U.S. Promising oncofetal antigens for CAR T-cells in adult cancers include the carcinoembryonic antigen (CEA) (NCT02349724), claudin 6 (CLDN6) (NCT04503278), or tumor-associated glycoprotein 72 (NCT05225363). Here, CLDN6 is linked to cancer.